OncoMatch/Clinical Trials/NCT06627244
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
Is NCT06627244 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Tebentafusp for metastatic uveal melanoma.
Treatment: Tebentafusp — The purpose of this study is to determine the effects (good and bad) that Tebentafusp in combination with Yttrium-90 (Y-90) radioembolization has on patients with metastatic uveal melanoma that has spread to the liver.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Biomarker criteria
Required: HLA-A A*02:01 positive
Human leukocyte antigen-A*02:01(HLA A⁕ 02:01) positive
Disease stage
Required: Stage IV
Metastatic disease required
Metastatic uveal melanoma, confined mainly to the liver
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radioembolization or other regional, liver-directed therapy
Lab requirements
Blood counts
Absolute neutrophil count (ANC) < 1.0 × 10^9 cells/L; Absolute lymphocyte count < 0.5 × 10^9 cells/L; Platelet count < 75 × 10^9 platelets/L; Hemoglobin < 8 g/dL
Liver function
Serum bilirubin <2 mg/dl, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5 x upper limit of normal (ULN); Exclusion: Total bilirubin > 1.5 × ULN, except for patients with Gilbert's syndrome, who are excluded if total bilirubin > 3.0 × ULN or direct bilirubin > 1.5 × ULN; ALT > 3 × ULN; AST > 3 × ULN
Cardiac function
Clinically significant cardiac disease or impaired cardiac function, including: congestive heart failure (NYHA Class ≥ 3), uncontrolled hypertension (systolic BP > 160 mmHg or diastolic BP > 110 mmHg), history of ventricular arrhythmia currently requiring medical treatment, uncontrolled atrial fibrillation, ECG QTcF > 470 msec or known history of congenital prolonged QT syndrome, acute myocardial infarction or unstable angina pectoris ≤ 6 months prior to screening
Serum bilirubin <2 mg/dl, AST and ALT < 5 x ULN; Exclusion: Total bilirubin > 1.5 × ULN, except for patients with Gilbert's syndrome, who are excluded if total bilirubin > 3.0 × ULN or direct bilirubin > 1.5 × ULN; ALT > 3 × ULN; AST > 3 × ULN; ANC < 1.0 × 10^9 cells/L; Absolute lymphocyte count < 0.5 × 10^9 cells/L; Platelet count < 75 × 10^9 platelets/L; Hemoglobin < 8 g/dL; Cardiac disease as detailed
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami · Miami, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06627244 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radioembolization or other regional, liver-directed therapy disqualifies patients from enrollment.
Does this trial require HLA-A?
Yes, HLA-A A*02:01 positive is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages